Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?

Diabetic nephropathy (DN), one of the most serious microvascular complications of diabetes mellitus (DM), may progress to end-stage renal disease (ESRD). Current biochemical biomarkers, such as urinary albumin excretion rate (UAER), have limitations for early screening and monitoring of DN. Recent s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Xiaodie, Yang, Min, Ling, Peiyao, Wu, Aihua, Zhou, Hua, Jiang, Jingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811266/
https://www.ncbi.nlm.nih.gov/pubmed/35125878
http://dx.doi.org/10.2147/DMSO.S350233
_version_ 1784644393478651904
author Mu, Xiaodie
Yang, Min
Ling, Peiyao
Wu, Aihua
Zhou, Hua
Jiang, Jingting
author_facet Mu, Xiaodie
Yang, Min
Ling, Peiyao
Wu, Aihua
Zhou, Hua
Jiang, Jingting
author_sort Mu, Xiaodie
collection PubMed
description Diabetic nephropathy (DN), one of the most serious microvascular complications of diabetes mellitus (DM), may progress to end-stage renal disease (ESRD). Current biochemical biomarkers, such as urinary albumin excretion rate (UAER), have limitations for early screening and monitoring of DN. Recent studies have identified some metabolites as candidate biomarkers for early detection of DN. In this review, we summarize the role of dysregulated acylcarnitines (AcylCNs) in DN pathophysiology. Lower abundance of short- and medium-chain AcylCNs and higher long-chain AcylCNs often occurred in DM with normal albuminuria and microalbuminuria, compared with advanced stages of DN. The increase of long-chain AcylCNs was supposed to be an adaptive compensation in fat acids (FAs) oxidation in the early stage of DN. Conversely, the decrease of long-chain AcylCNs was due to incomplete oxidation of FAs in advanced stage of DN. Thus, AcylCNs may serve as sensitive biomarkers in predicting the risk of DN.
format Online
Article
Text
id pubmed-8811266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88112662022-02-04 Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy? Mu, Xiaodie Yang, Min Ling, Peiyao Wu, Aihua Zhou, Hua Jiang, Jingting Diabetes Metab Syndr Obes Review Diabetic nephropathy (DN), one of the most serious microvascular complications of diabetes mellitus (DM), may progress to end-stage renal disease (ESRD). Current biochemical biomarkers, such as urinary albumin excretion rate (UAER), have limitations for early screening and monitoring of DN. Recent studies have identified some metabolites as candidate biomarkers for early detection of DN. In this review, we summarize the role of dysregulated acylcarnitines (AcylCNs) in DN pathophysiology. Lower abundance of short- and medium-chain AcylCNs and higher long-chain AcylCNs often occurred in DM with normal albuminuria and microalbuminuria, compared with advanced stages of DN. The increase of long-chain AcylCNs was supposed to be an adaptive compensation in fat acids (FAs) oxidation in the early stage of DN. Conversely, the decrease of long-chain AcylCNs was due to incomplete oxidation of FAs in advanced stage of DN. Thus, AcylCNs may serve as sensitive biomarkers in predicting the risk of DN. Dove 2022-01-29 /pmc/articles/PMC8811266/ /pubmed/35125878 http://dx.doi.org/10.2147/DMSO.S350233 Text en © 2022 Mu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mu, Xiaodie
Yang, Min
Ling, Peiyao
Wu, Aihua
Zhou, Hua
Jiang, Jingting
Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
title Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
title_full Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
title_fullStr Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
title_full_unstemmed Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
title_short Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?
title_sort acylcarnitines: can they be biomarkers of diabetic nephropathy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811266/
https://www.ncbi.nlm.nih.gov/pubmed/35125878
http://dx.doi.org/10.2147/DMSO.S350233
work_keys_str_mv AT muxiaodie acylcarnitinescantheybebiomarkersofdiabeticnephropathy
AT yangmin acylcarnitinescantheybebiomarkersofdiabeticnephropathy
AT lingpeiyao acylcarnitinescantheybebiomarkersofdiabeticnephropathy
AT wuaihua acylcarnitinescantheybebiomarkersofdiabeticnephropathy
AT zhouhua acylcarnitinescantheybebiomarkersofdiabeticnephropathy
AT jiangjingting acylcarnitinescantheybebiomarkersofdiabeticnephropathy

Ejemplares similares